Richard Scolyer's Death, Brain Cancer Research
Analysis based on 34 articles · First reported Jun 07, 2026 · Last updated Jun 08, 2026
The death of Richard Scolyer, a pioneering cancer researcher, after undergoing a world-first experimental brain cancer treatment, highlights the potential for new medical breakthroughs. The ongoing clinical trial in the United States, based on his and Georgina Long's work, could significantly impact the biotechnology and pharmaceutical industries by revolutionizing glioblastoma treatment, potentially leading to new drug development and investment opportunities.
Richard Scolyer, a world-renowned melanoma pathologist and co-medical director of The Australia Institute, died at 59 after a battle with glioblastoma, an aggressive brain cancer. Diagnosed in June 2023 with a prognosis of six to eight months, Scolyer undertook a world-first experimental treatment based on his and Georgina Long's melanoma research. This treatment involved pre-surgery immunotherapy and a personalized vaccine, which extended his life for almost two years. Scolyer publicly documented his journey, sharing insights and advancing scientific understanding. His work has led to an early-stage clinical trial in the United States, aiming to replicate these promising results for other brain cancer patients. Australia recognized Scolyer and Long as joint 'Australian of the Year' in 2024, and Prime Minister Anthony Albanese committed $5.9 million to establish the Richard Scolyer Chair in Brain Cancer Research at Chris O Brien Lifehouse in Sydney.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard